Reviews Fentanyl Iontophoretic Transdermal System


No reviews yet.

Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006





Other reviews about Fentanyl Iontophoretic Transdermal System on wordpress

Emerging treatment modalities: Balancing efficacy and safety.
  by FMS Global News
Am J Health Syst Pharm. 2007 Mar 15;64(6 Suppl 4):S6-S11. Viscusi ER. Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, PA. PURPOSE: The advantages and disadvantages of intravenous patient-controlled analgesia (i.v. […]


Cadence Pharmaceuticals Signs Option Agreement to Acquire Incline Therapeutics
  by Biotechtrader
Company Also Closes $30 Million Debt Financing SAN DIEGO, June 21, 2010 /PRNewswire via COMTEX/ -- Cadence Pharmaceuticals, Inc. (CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing […]


Two, or perhaps more, of t
  by poxrpkrpzcmgw
He had had a great shock when she had told him their love had been always a conflict. You say yourself youre not sure whether you can come […]



Other reviews about Fentanyl Iontophoretic Transdermal System on web:

Learn about the prescription medication Ionsys (Fentanyl Iontophoretic Transdermal System), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Ionsys (Fentanyl Iontophoretic Transdermal System) Drug ...


- Transdermal System 7.5 mg. Trade Names: Duragesic-100 - Transdermal System 10 mg. Trade Names: Ionsys - Iontophoretic Transdermal System 10.8 mg. RAN-Fentanyl Transdermal System (Canada) Complete Fentanyl Transdermal System information from Drugs.com


脙聜脗漏 The Board of Management and Trustees of the British Journal of Anaesthesia 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org Fentanyl HCl iontophoretic transdermal system (ITS): clinical ...


Abstract and Introduction: IONSYS is successful in controlling acute postoperative pain that circumvents the limitations of intravenous patient-controlled analgesia. Fentanyl HCl Patient-Controlled Iontophoretic Transdermal System ...


FORMULARY DRUG REVIEWS 1076 Volume 41, November 2006 Hospital Pharmacy Volume 41, Number 11, pp 1076-1085 2006 Wolters Kluwer Health, Inc. Fentanyl Iontophoretic Transdermal System Dennis ... Fentanyl Iontophoretic Transdermal System


Beerse, Belgium (January 14, 2008) 脙垄脗聙脗聯 Janssen-Cilag International NV announced today that IONSYS脙垄脗聞脗垄 (fentanyl iontophoretic transdermal system), a new innovative, needle-free ... IONSYS脙垄脗聞脗垄, the highly innovative needle-free system for the ...


ALZA Corporation Receives FDA Approval for Ionsys (Fentanyl Iontophoretic Transdermal System) News - ALZA Corporation Receives FDA Approval for Ionsys (Fentanyl ...


British Journal of Anaesthesia 2007 98(6):806-815; doi:10.1093/bja/aem102 Iontophoretic transdermal system using fentanyl compared with ...


1. Reg Anesth Pain Med. 2006 Nov-Dec;31(6):546-54. Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine ... Fentanyl iontophoretic transdermal system for acute-pain ...


The Annals of Pharmacotherapy: Vol. 40, No. 12, pp. 2178-2186. DOI 10.1345/aph.1H135 脙聜脗漏 2006 Harvey Whitney Books Company. Fentanyl HCl Patient-Controlled Iontophoretic Transdermal System ...





Featured Reviews

Reviews Pediarix

Pediarix Drug Description PEDIARIX® [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed,  Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined] DRUG DESCRIPTION What are the possible side...
Read More  |  Review This
Reviews Hydrocodone Bitartrate and Acetaminophen Tablets

Lortab 7.5 Drug Description LORTAB® 7.5/500 (hydrocodone bitartrate and acetaminophen) Tablets, USP 7.5 mg/500 mg DRUG DESCRIPTION Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration. WARNING:...
Read More  |  Review This
Reviews Biavax

Biavax Drug Description DRUG DESCRIPTION BIAVAX® II (Rubella and Mumps Virus Vaccine Live) is a live virus vaccine for immunization against rubella (German measles) and mumps. BIAVAX II is a sterile lyophilized preparation...
Read More  |  Review This
Reviews HyperHep B

HyperHep B Drug Description HyperHEP B™ S/D Hepatitis B Immune Globulin (Human) Solvent/Detergent Treated DRUG DESCRIPTION What are the possible side effects of hepatitis B immune globulin (HepaGam B, HepaGam B NovaPlus,...
Read More  |  Review This
Reviews Ciprodex

Ciprodex Drug Description CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension DRUG DESCRIPTION What are the possible side effects of ciprofloxacin and dexamethasone otic (Ciprodex)? Stop using...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....